Q-omics provides the consensus-scored RBMXL1 profile across patient tissues and cancer cell-line models. RBMXL1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, RBMXL1 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, RBMXL1 RNA expression shows 20,846 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SCLC, KICH, and THYM as cancer lineages where RBMXL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBMXL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBMXL1 survival associations across molecular data types. RBMXL1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBMXL1 RNA expression–survival associations across cancer types. High RBMXL1 expression shows unfavorable associations in LIHC and PAAD, but favorable associations in SCLC, BRCA, KIRC and UCS. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for RBMXL1 RNA expression.
This table summarizes RBMXL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RBMXL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBMXL1 shows lower tumor expression in KICH, THCA, LUAD, BRCA, KIRC and KIRP. The KICH box plot shows higher RBMXL1 RNA expression in normal versus tumor tissue (log2 FC = −2.097, t-test p < 0.001).
This table shows molecular features associated with RBMXL1 in patient tissues and cancer cell lines. In patient samples, RBMXL1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RBMXL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
